COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis.

Date publication

mai 2022

Journal

JTO clinical and research reports

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline

Tous les auteurs :
Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Mazieres J, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35619644

Résumé

The Thoracic Centers International COVID-19 Collaboration (TERAVOLT) registry found ∼ 30% mortality in patients with thoracic malignancies during the initial COVID surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave, and efficacy of vaccination.

Référence

JTO Clin Res Rep. 2022 05 20;:100335